Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.
Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.
Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.
Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.
Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of
Amgen has released positive results from two open-label extension studies evaluating the long-term safety and tolerability of Repatha (evolocumab) in over 6,600 patients. These studies, following the Phase 3 FOURIER trial, show that Repatha is safe for extended use, with no new safety issues reported over five years. More than 85% of patients achieved LDL-C levels below 40 mg/dL. Amgen emphasizes Repatha's sustained effectiveness in lowering LDL-C in patients with atherosclerotic cardiovascular disease, reinforcing its position as a leader in PCSK9 inhibitors.
Amgen (NASDAQ:AMGN) plans to announce its first quarter financial results on April 27, 2022, after U.S. market close, followed by a conference call at 2:00 p.m. PT. The call will include CEO Robert A. Bradway and senior management, and will be accessible via live audio broadcast online. The conference will discuss Amgen's ongoing commitment to developing innovative therapies and its strong market position as a leading biotechnology company since 1980. More information and the webcast can be found on Amgen's website.
Amgen announced preliminary results from a Phase 3 study of ABP 654, a biosimilar candidate to STELARA (ustekinumab), for treating moderate to severe plaque psoriasis. The primary efficacy analysis showed no clinically meaningful differences between ABP 654 and STELARA, with a mean difference of 0.14 in percentage improvement in psoriasis area severity index (PASI) from baseline to week 12. The safety profile was comparable between both treatments. Amgen aims to expand its biosimilars portfolio, which includes 11 candidates.
Amgen announced significant long-term clinical results from the CodeBreaK 100 trial, focusing on its KRASG12C inhibitor, LUMAKRAS® (sotorasib), for advanced non-small cell lung cancer (NSCLC). In this two-year follow-up of 174 patients, a 40.7% objective response rate (ORR) was observed, with a disease control rate (DCR) of 83.7%. The median duration of response was 12.3 months, and overall survival reached 12.5 months. Importantly, no new safety concerns were reported, affirming LUMAKRAS's position as a leading treatment for KRAS G12C-mutated NSCLC.
Amgen presented new data on Otezla (apremilast) for treating plaque psoriasis at the American Academy of Dermatology congress in Boston from March 25-29, 2022. This data reinforces its clinical benefits for patients with mild to moderate plaque psoriasis and palmoplantar pustulosis. Otezla is the first FDA-approved oral therapy for plaque psoriasis across all severity levels. Key results from ongoing studies, including PROMINENT and ADVANCE, demonstrate Otezla's efficacy, while safety profiles remain consistent with prior findings. Major abstracts will be presented on March 27, 2022.
Amgen will present virtually at the 32nd Annual Oppenheimer Healthcare Conference on March 16, 2022, at 11:20 a.m. ET. The presentation will be conducted by Rob Lenz, M.D., Ph.D., and Peter H. Griffith, focusing on Amgen's business developments. The webcast will be accessible to the public through Amgen's website, with an archive available for 90 days post-event. Amgen is a leading biotechnology firm, committed to improving health outcomes through innovative human therapeutics, and is recognized as one of the top sustainable companies globally.
Amgen (NASDAQ: AMGN) will present crucial data from its oncology portfolio at the AACR Annual Meeting in New Orleans, April 8-13, 2022. A highlight will be the late-breaking oral presentation of long-term outcomes from the CodeBreaK 100 trial for LUMAKRAS® (sotorasib), a KRASG12C inhibitor for non-small cell lung cancer (NSCLC), on April 10. Additional data will cover preclinical results from AMG 794 and TNB-928b. Over 40 countries have approved LUMAKRAS, which has been administered to more than 4,000 patients globally.
Amgen (NASDAQ:AMGN) has commenced construction on a new biomanufacturing facility in Holly Springs, North Carolina, aimed to be operational by 2025. This facility will enhance Amgen's capability to meet the rising demand for its medicines targeting severe health issues like cancer and heart disease, creating over 350 high-quality jobs.
The plant will utilize advanced technologies to maximize production efficiency and adhere to strict environmental standards, supporting Amgen's goal of carbon neutrality by 2027.
Amgen will virtually present at the 42nd Annual Cowen Healthcare Conference on March 8, 2022, at 11:10 a.m. ET. Key executives, Murdo Gordon and Peter H. Griffith, will lead the presentation. Interested parties can access the conference via a live webcast on Amgen's website, which will also archive the event for 90 days. Amgen, a leading biotechnology company, focuses on innovative human therapeutics and has been recognized for its workplace and sustainability efforts.
Amgen's Board of Directors has declared a $1.94 per share dividend for the second quarter of 2022. This dividend will be paid on June 8, 2022, to stockholders of record by the close of business on May 17, 2022. Amgen, a leader in biotechnology since 1980, focuses on innovative therapeutics aimed at serious illnesses. The company is recognized for its commitment to sustainability and workplace excellence, being listed among the 25 World's Best Workplaces™ and 100 most sustainable companies globally.
FAQ
What is the current stock price of Amgen (AMGN)?
What is the market cap of Amgen (AMGN)?
